|Dr. Gil Van Bokkelen||Co-Founder, Chairman & CEO||659.24k||N/A||1961|
|Mr. William B. J. Lehmann Jr.||Pres, COO & Sec.||506.97k||N/A||1966|
|Dr. John J. Harrington||Co-Founder, Chief Scientific Officer, Exec. VP & Director||502.1k||N/A||1967|
|Ms. Laura K. Campbell||Sr. VP of Fin.||335.2k||N/A||1964|
|Dr. Manal Morsy M.D., PH.D.||Sr. VP & Head of Global Regulatory Affairs||N/A||N/A||N/A|
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which has completed Phase II study for treating patients suffering from moderate and severe ischemic stroke; that is in Phase II clinical study for treating patients with acute myocardial infarction; and, which is in Phase I/II clinical study for treating patients with acute respiratory distress syndrome, as well as that has completed Phase I clinical study for patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical need. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke in Japan; RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; the University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets for compound screening and development. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
Athersys, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 5. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 2; Compensation: 8.